SEC Form 10-K filed by Acrivon Therapeutics Inc.
$ACRV
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/5/2025 | $6.00 | Overweight | Piper Sandler |
| 1/31/2025 | Overweight | KeyBanc Capital Markets | |
| 9/16/2024 | $16.00 | Neutral → Buy | Ladenburg Thalmann |
| 4/29/2024 | Buy → Neutral | Ladenburg Thalmann | |
| 3/1/2024 | $14.00 | Mkt Outperform | JMP Securities |
| 12/15/2023 | $17.00 → $12.00 | Buy | Jefferies |
| 10/5/2023 | Buy | Maxim Group | |
| 6/2/2023 | $25.00 | Outperform | Oppenheimer |
S-8 - Acrivon Therapeutics, Inc. (0001781174) (Filer)
8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
10-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC) Late-breaking oral presentation and corporate KOL panel at ESGO 2026 highlighted strong ACR-368 data in serous EC, a high unmet need subtype responsible for ~50% of EC mortality Initiated Arm 3 (ACR-368 + ultra low-dose gemcitabine) and adding Arm 4 (ACR-368) Phase 2b cohorts in all-comer (biopsy-independent) serous EC subjects Initial Phase 1 ACR-2316 data in AP3-prioritized solid tumor types showed favorable tolerability and promising clinical activity, notably in heavily pre-treated lung cancer subjects Cash, cash equivale
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (ADCs) ACR-2316, a WEE1/PKMYT1 inhibitor currently in Phase 1, demonstrated complete and durable tumor regression in immunocompetent, syngeneic tumor mouse models in combination with anti-PD-L1 checkpoint inhibition WATERTOWN, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Monday, March 2, 2026, at 1:50 p.m. ET at the TD Cowen 46th Annual Health Care Conference in Boston. The live and archived webcast of this event can be acces
Piper Sandler resumed coverage of Acrivon Therapeutics with a rating of Overweight and set a new price target of $6.00
KeyBanc Capital Markets initiated coverage of Acrivon Therapeutics with a rating of Overweight
Ladenburg Thalmann upgraded Acrivon Therapeutics from Neutral to Buy and set a new price target of $16.00
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall response rate (ORR) and 44% in subjects with ≤2 prior lines of therapy* Analysis of data from all-comer subjects with serous subtype and ≤2 prior lines of therapy, a high unmet need population, showed a confirmed ORR (cORR) of 52%, and within BM+ subjects cORR was 67%, consistent with higher BM levels across serous subjects Arm 3 is enrolling up to 90 subjects with serous subtype and ≤2 prior lines of therapy, without requirement for a tumor biopsy, for treatment with ACR-368 plus ultra-low d
WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical development, today announced it will be providing ACR-368 and ACR-2316 clinical data and other updates via a press release at 7:30 a.m. ET, and conference call and webcast at 8:30 a.m. ET, both on Thu
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical development, today announced it will be providing ACR-368 and ACR-2316 clinical data and other updates via a conference call and webcast in January 2026. Topics will include: Updated interim ACR-368
SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)
SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)
SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)
Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology over the past decades Will lead all clinical development -- including the ongoing ACR-368 Phase 2b registrational-intent trial in endometrial cancer towards regulatory submission and potential approval, and the ongoing ACR-2316 Phase 1 study in selected solid tumor types WATERTOWN, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acriv
WATERTOWN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided business highlights. "On the heels of a productive 2023, we are off to a tremendous start in 2024, which is an important and data-driven year
WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors. "Santhosh previously served as an advisor to Acrivon and has a deep understanding and appreciation of the breadth and novelty of our next generation precisi